SCHEMBL7212426

SCHEMBL7212426

CCNc1ccc2c(c1)CCC2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.53
MAPT P10636 6/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
NPC1 O15118 5/20 0.51
RAB9A P51151 5/20 0.51
POLB P06746 5/20 0.51
KDM4E B2RXH2 4/20 0.51
GAA P10253 2/20 0.51
ALOX15 P16050 1/20 0.51
RAPGEF4 Q8WZA2 1/20 0.50
TDP1 Q9NUW8 2/20 0.48
ADRA2A P08913 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
LMNA P02545 1/20 0.45
THRB P10828 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10747423 0.96 ALDH1A1 (0.53) ALDH1A1MAPTMEN1KMT2ANPC1
SCHEMBL13911196 0.85 ALDH1A1 (0.50) ALDH1A1MAPTMEN1KMT2ANPC1
SCHEMBL23174566 0.81 ALDH1A1 (0.50) ALDH1A1MAPTMEN1KMT2ANPC1
SCHEMBL6060993 0.80 ALDH1A1 (0.49) ALDH1A1MAPTMEN1KMT2ANPC1
SCHEMBL13900459 0.79 ALDH1A1 (0.49) ALDH1A1MAPTMEN1KMT2ANPC1
SCHEMBL7427500 0.78 SYK (0.38) ALDH1A1MAPTMEN1KMT2ANPC1
SCHEMBL24535431 0.77 MAPT (0.47) ALDH1A1MAPTMEN1KMT2ANPC1
SCHEMBL4546338 0.77 RAPGEF4 (0.55) ALDH1A1MAPTMEN1KMT2ANPC1
SCHEMBL30558478 0.77 RAPGEF4 (0.55) ALDH1A1MAPTMEN1KMT2ANPC1
SCHEMBL2484588 0.77 ASIC3 (0.50) ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111848494-B Guanidine compounds and uses thereof 伊谬诺米特医疗有限公司 2023-08-01 CN disclosed
EP-3131877-B1 BIGUANIDE COMPOUNDS IMMUNOMET THERAPEUTICS INC (US) 2023-07-19 EP disclosed
WO-2023275193-A1 COMPOSITION COMPRISING AT LEAST ONE OXIDATION DYE, 1,3-PROPANEDIOL, AT LEAST ONE ALKALINE AGENT AND AT LEAST ONE FATTY SUBSTANCE L'OREAL (FR) 2023-01-05 WO disclosed
WO-2023275197-A1 COMPOSITION COMPRISING AT LEAST ONE OXIDATION DYE, AT LEAST ONE ALKALINE AGENT AND AT LEAST ONE LIQUID FATTY ALCOHOL AND AT LEAST ONE SOLID FATTY ALCOHOL L'OREAL (FR) 2023-01-05 WO disclosed
US-11465989-B2 Guanidine compounds and use thereof ImmunoMet Therapeutics, Inc. (US) 2022-10-11 US disclosed
WO-2022129355-A1 COSMETIC COMPOSITION COMPRISING A COMBINATION OF TWO PARTICULAR COUPLERS AND A NONIONIC SURFACTANT OF ALKYLPOLYGLYCOSIDE TYPE L'OREAL (FR) 2022-06-23 WO disclosed
WO-2022129352-A1 COSMETIC COMPOSITION COMPRISING A COMBINATION OF TWO PARTICULAR COUPLERS AND N,N-DICARBOXYMETHYLGLUTAMIC ACID AND/OR ITS SALTS L'OREAL (FR) 2022-06-23 WO disclosed
WO-2022129389-A1 COMPOSITION COMPRISING A PARTICULAR OXIDATION DYEING BASE, AT LEAST ONE PARTICULAR COUPLER AND AT LEAST ONE FATTY SUBSTANCE L'OREAL (FR) 2022-06-23 WO disclosed
EP-3904354-A1 NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 Perha Pharmaceuticals (FR) 2021-11-03 EP disclosed
EP-3828174-A1 PYRIDAZINONE DERIVATIVE Sumitomo Dainippon Pharma Co., Ltd. (JP) 2021-06-02 EP disclosed
US-20090048244-A1 PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2009-02-19 US disclosed
US-7297695-B2 Pyrrolotriazine compounds as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-20 US disclosed
US-20070093502-A1 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication BONFANTI JEAN-FRANCOIS 2007-04-26 US disclosed
US-20070093502-A1 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication BONFANTI JEAN-FRANCOIS 2007-04-26 US disclosed
WO-2005058874-A1 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION TIBOTEC PHARMACEUTICALS LTD. (IE) 2005-06-30 WO disclosed
EP-1148876-A4 CALCILYTIC COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2003-07-23 EP disclosed
EP-1148876-A1 CALCILYTIC COMPOUNDS SmithKline Beecham Corporation (US) 2001-10-31 EP disclosed
WO-2000045816-A1 CALCILYTIC COMPOUNDS SMITHKLINE BEECHAM CORPORATION (GB) 2000-08-10 WO disclosed
US-4695571-A Tricyclic oxindole antiinflammatory agents PFIZER INC. (US) 1987-09-22 US disclosed
WO-1986001510-A1 TRICYCLIC OXINDOLE ANTIINFLAMMATORY AGENTS PFIZER INC. (US) 1986-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11465989-B2 Guanidine compounds and use thereof PC, TFAM, PCK2 ALDH1A1 1471/4885MAPT 795/4885MEN1 4540/4885
US-20070093502-A1 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SUB1, HYOU1 ALDH1A1 3108/4885MAPT 4884/4885MEN1 2273/4885
US-20090048244-A1 PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS ERBB2, ERBB4, ERBB3 ALDH1A1 3252/4885MAPT 2432/4885MEN1 3024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.